Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537725 | 0.71 | CRHR1 (0.59) | CRHR1ALDH1A1KDM4E | |
| SCHEMBL18134204 | 0.67 | CCNA2 (0.44) | ALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL11555941 | 0.67 | PKM (0.34) | KMT2AALDH1A1MEN1 | |
| SCHEMBL548076 | 0.66 | CA1 (0.52) | HSP90AA1HSP90AB1TDP1KMT2ACYP3A4 | |
| SCHEMBL358973 | 0.65 | ALDH1A1 (0.59) | MCHR1TDP1DCPSCYP3A4ALDH1A1 | |
| SCHEMBL1092368 | 0.65 | TOP1 (0.52) | HSP90AA1HSP90AB1TDP1KMT2ACYP3A4 | |
| SCHEMBL28148154 | 0.65 | CA1 (0.65) | TDP1KMT2ACYP3A4ALDH1A1ADRA2B | |
| SCHEMBL7276398 | 0.64 | ALDH1A1 (0.65) | HSP90AA1HSP90AB1MCHR1TDP1KMT2A | |
| SCHEMBL30816756 | 0.64 | ALDH1A1 (0.65) | HSP90AA1HSP90AB1MCHR1TDP1KMT2A | |
| SCHEMBL14450999 | 0.64 | CA1 (0.50) | HSP90AA1HSP90AB1TDP1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233949-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020072521-A1 | 5-substituted arylpyrimidines | NEUROGEN CORPORATION | 2002-06-13 | — | — | US | disclosed |
| WO-2001068614-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072521-A1 | 5-substituted arylpyrimidines | HTR5A, CRHR1, HTR4 | CRHR1 2/4885HSP90AA1 3611/4885HSP90AB1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.